Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
Status:
Recruiting
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects, safety, and effectiveness of low dose
radiation to the entire body (total body irradiation [TBI]) and higher dose radiation to
known areas of cancer (hypofractionated radiation therapy [H-RT]) combined with atezolizumab
and chemotherapy (carboplatin & etoposide) in treating patients with small cell lung cancer
that has spread to disease sites outside of the lung (extensive stage). Extensive stage
disease has historically been treated with chemotherapy alone with consideration of chest
(thoracic) radiation therapy for those with response to chemotherapy, as well as
consideration of preventative radiation therapy to the head (prophylactic cranial
irradiation). Emerging evidence supports the synergistic interactions between immunotherapy
and radiation therapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Carboplatin is in a class of medications known as
platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin,
but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing
the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin
derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill
tumor cells. Combining TBI and H-RT with atezolizumab and chemotherapy may improve response
to treatment.